Spondyloarthritis & psoriatic arthritis
Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort
Authors' conclusion
This prospective, real-life study found a better persistence of ustekinumab than TNFi in PsA patients. At 1 year, both treatments showed similar effectiveness.
Study context
- Population
- Italian psoriatic arthritis (PsA) patients enrolled in the PsABio studyeffectiveness set
- Participants
- 222 patients
- Exposure
- Ustekinumab vs TNF inhibitors (TNFi) in PsA
- Ustekinumabn = 101
- TNFin = 121reference
- Outcome
- Treatment persistence
- Follow-up
- Up to 12±3 months
Methodological detailsreal-world, propensity score adjustment, non-response imputation
- Real-world
- Propensity score adjustment
- Non-response imputation
Main finding
As reported in the abstract
Propensity score (PS)-adjusted HR of treatment discontinuation
0.46
95% CI 0.26–0.82
By group
Observational data: associations, not effects.
Further findings
cDAPSA LDA/remission · 1 year
MDA · 1 year
Persistence in subgroups (females, monotherapy without MTX, BMI <25 or >30 kg/m², ustekinumab as 2nd-line instead of a second TNFi)
- Ustekinumab showed better persistence than TNFi
cDAPSA LDA/remission · 1 year
- After PS adjustment, ORs of clinical effectiveness did not differ significantly
Original publication
Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort. Clin Exp Rheumatol. Published 9 March 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →